Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Autolus Therapeutics (Nasdaq: AUTL), a clinical-stage biopharmaceutical company focused on programmed T cell therapies, will release its third quarter 2024 financial results before US markets open on November 12, 2024. The company will host a conference call and webcast at 8:30 am EDT/1:30 pm BST, where management will discuss financial results and provide a business update. Participants must pre-register to receive dial-in details and a personal PIN for the call.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie con cellule T programmate, pubblicherà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura dei mercati statunitensi il 12 novembre 2024. L'azienda organizzerà una conferenza telefonica e un webcast alle 8:30 EDT/1:30 BST, durante il quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento sull'attività. I partecipanti devono registrarsi in anticipo per ricevere i dettagli per la chiamata e un PIN personale.
Autolus Therapeutics (Nasdaq: AUTL), una empresa biofarmacéutica en etapa clínica centrada en terapias de células T programadas, publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura de los mercados en EE. UU. el 12 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:30 a.m. EDT/1:30 p.m. BST, donde la dirección discutirá los resultados financieros y proporcionará una actualización del negocio. Los participantes deben registrarse con anticipación para recibir los detalles de marcación y un PIN personal para la llamada.
Autolus Therapeutics (Nasdaq: AUTL)는 프로그래밍된 T세포 치료에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 3분기 재무 결과를 미국 시장이 열기 전인 2024년 11월 12일에 발표할 예정입니다. 회사는 동부 표준시 기준 오전 8시 30분/영국 여름 시간 기준 오후 1시 30분에 재무 결과와 사업 업데이트를 논의하는 컨퍼런스 콜 및 웹캐스트를 진행합니다. 참가자는 전화 연결 세부정보와 개인 PIN을 받기 위해 사전 등록해야 합니다.
Autolus Therapeutics (Nasdaq: AUTL), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules T programmées, publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés américains le 12 novembre 2024. L'entreprise organisera une conférence téléphonique et un webcast à 8h30 EDT/13h30 BST, au cours desquels la direction discutera des résultats financiers et donnera une mise à jour sur les activités. Les participants doivent s'inscrire à l'avance pour recevoir les détails de connexion et un code PIN personnel pour l'appel.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf programmierte T-Zelltherapien konzentriert, wird seine Finanzergebnisse für das dritte Quartal 2024 vor der Eröffnung der US-Märkte am 12. November 2024 veröffentlichen. Das Unternehmen wird um 8:30 Uhr EDT/13:30 Uhr BST eine Telefonkonferenz und einen Webcast abhalten, in dem das Management die Finanzergebnisse besprechen und ein Geschäftsupdate geben wird. Die Teilnehmer müssen sich im Voraus registrieren, um die Einwahldaten und eine persönliche PIN für den Anruf zu erhalten.
- None.
- None.
LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024.
Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
Contact:
Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
When will Autolus Therapeutics (AUTL) release Q3 2024 earnings?
What time is Autolus Therapeutics (AUTL) Q3 2024 earnings call?
How can I access Autolus Therapeutics (AUTL) Q3 2024 earnings call?
